If you’re eyeing Pfizer stock and wondering what’s next, you’re definitely not alone. The last few years have been a roller ...

Pfizer (PFE) shares have been inching upward recently, sparking some fresh attention from investors looking to understand ...

Pfizer (NYSE: PFE) continues to lag the market. Over the past few years, the company has generally reported declining revenue and profits, resulting in a substantial decline in market value. The ...

Pfizer's stock has been struggling for multiple years, and even a low valuation hasn't made it an enticing option for many investors.

After its best day in nearly four years Tuesday, Pfizer stock gave an encore performance. Shares of the drugmaker closed u ...

Pfizer Inc. is a global biopharmaceutical leader with a diversified product portfolio and significant scale, supported by ...

Over the past decade, pharmaceutical maker Pfizer ( PFE -0.53%) has severely lagged the market. Dividends reinvested aside, ...

Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...

Pfizer acquired a smaller company for $4.9 billion to improve its prospects in the GLP-1 market. The pharmaceutical giant could carve out a small niche for itself in this growing space. Pfizer's ...

Pfizer (PFE) has seen its stock price move gradually higher over the past week, rising nearly 15% in that period. Investors seem interested in the company’s recent performance and underlying ...

Pfizer is getting its hands on a promising weight management candidate. The company's recent deal with the U.S. government eliminates a major risk. The stock's valuation looks attractive right now.

Pfizer (NYSE: PFE) continues to lag the market. Over the past few years, the company has generally reported declining revenue and profits, resulting in a substantial decline in market value. The ...